← Leaderboards
Donald P McDonnell
Duke University
$25,108,849
Attributed
$25,108,849
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,108,849 · 16
By mechanism
R01$18,918,428 · 10
R37$4,961,935 · 1
R21$527,291 · 1
P50$358,444 · 1
P30$326,751 · 1
R13$16,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Erik Russell Nelson$3,194,432
- Carolyn B Coyne$16,278,724
- Mary Min-Chin Lee$2,922,536
- Ketan B Ghaghada$911,302
- Edward A Miao$16,675,058
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Breast NeoplasmResponseReceptorNuclear ReceptorsComplexCellsPathway InteractionsTumorPharmacologyEstrogensTissuesGrowthTherapeutic TargetInsightEstrogen ReceptorsBiologicalBaseProteinsEstrogen Receptor ModulatorsCofactorEstrogen AntagonistsGenesBiology
Grant awards (72)
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens$588,140
R01 · FY2025 · CA · contact PI
Manipulating normal estrogen physiology as a therapeutic approach in cancer$542,002
R01 · FY2025 · CA · contact PI
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens$575,405
R01 · FY2024 · CA · contact PI
Manipulating normal estrogen physiology as a therapeutic approach in cancer$514,902
R01 · FY2024 · CA · contact PI
Women's Cancer Program$59,878
P30 · FY2024 · CA · contact PI
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens$607,819
R01 · FY2023 · CA · contact PI
Manipulating normal estrogen physiology as a therapeutic approach in cancer$558,602
R01 · FY2023 · CA · contact PI
Development of Novel ERRalpha Antagonists as Breast Cancer Therapeutics$272,423
R21 · FY2023 · CA · contact PI
Women's Cancer Program$67,987
P30 · FY2023 · CA · contact PI
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens$665,035
R01 · FY2022 · CA · contact PI
Development of Novel ERRalpha Antagonists as Breast Cancer Therapeutics$254,868
R21 · FY2022 · CA · contact PI
Women's Cancer Program$67,602
P30 · FY2022 · CA · contact PI
Women's Cancer Program$64,722
P30 · FY2021 · CA · contact PI
Women's Cancer Program$66,562
P30 · FY2020 · CA · contact PI
ER and LXR as mediators of the pathobiology of hypercholesterolemia$520,829
R01 · FY2019 · DK · contact PI
ER and LXR as mediators of the pathobiology of hypercholesterolemia$520,829
R01 · FY2018 · DK · contact PI
ER and LXR as mediators of the pathobiology of hypercholesterolemia$520,829
R01 · FY2017 · DK · contact PI
The role of ERRalpha/PGC-1 in disease pathogenesis$314,209
R01 · FY2017 · CA · contact PI
ER and LXR as mediators of the pathobiology of hypercholesterolemia$520,829
R01 · FY2016 · DK · contact PI
The role of ERRalpha/PGC-1 in disease pathogenesis$314,209
R01 · FY2016 · CA · contact PI
ER and LXR as mediators of the pathobiology of hypercholesterolemia$528,943
R01 · FY2015 · DK · contact PI
The role of ERRalpha/PGC-1 in disease pathogenesis$314,209
R01 · FY2015 · CA · contact PI
Mechanism of Action of Estrogens and Antiestrogens$521,155
R37 · FY2014 · DK · contact PI
The role of ERRalpha/PGC-1 in disease pathogenesis$304,783
R01 · FY2014 · CA · contact PI
Mechanism of Action of Estrogens and Antiestrogens$500,031
R37 · FY2013 · DK · contact PI
Molecular Determinants of Androgen Receptor Pharmacology$325,169
R01 · FY2013 · CA · contact PI
The role of ERRalpha/PGC-1 in disease pathogenesis$322,347
R01 · FY2013 · CA · contact PI
Mechanism of Action of Estrogens and Antiestrogens$515,465
R37 · FY2012 · DK · contact PI
Molecular Determinants of Androgen Receptor Pharmacology$346,733
R01 · FY2012 · CA · contact PI
Validation of the Estrogen Related Receptor as a therapeutic target in cancer$324,903
R01 · FY2012 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$512,900
R37 · FY2011 · DK · contact PI
Molecular Determinants of Androgen Receptor Pharmacology$347,562
R01 · FY2011 · CA · contact PI
Validation of the Estrogen Related Receptor as a therapeutic target in cancer$324,903
R01 · FY2011 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$504,674
R37 · FY2010 · DK · contact PI
The pharmacological actions of antiprogestins in uterine fibroids$415,405
R01 · FY2010 · HD · contact PI
Molecular Determinants of Androgen Receptor Pharmacology$359,188
R01 · FY2010 · CA · contact PI
Validation of the Estrogen Related Receptor as a therapeutic target in cancer$328,185
R01 · FY2010 · DK · contact PI
Validation of the Estrogen Related Receptor as a therapeutic target in cancer$89,347
R01 · FY2010 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$83,915
R37 · FY2010 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$451,071
R37 · FY2009 · DK · contact PI
The pharmacological actions of antiprogestins in uterine fibroids$401,274
R01 · FY2009 · HD · contact PI
Molecular Determinants of Androgen Receptor Pharmacology$353,034
R01 · FY2009 · CA · contact PI
Validation of the Estrogen Related Receptor as a therapeutic target in cancer$331,500
R01 · FY2009 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$84,029
R37 · FY2009 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$437,931
R37 · FY2008 · DK · contact PI
Validation of the Estrogen Related Receptor as a therapeutic target in cancer$331,500
R01 · FY2008 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$433,853
R37 · FY2007 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$459,779
R37 · FY2006 · DK · contact PI
Molecular Determinants of Androgen Receptor Pharmacology$338,358
R01 · FY2006 · DK · contact PI
Mechanism of Action of Estrogens and Antiestrogens$457,132
R37 · FY2005 · DK
Development of peptide antagonists of estrogen signaling$412,886
R01 · FY2005 · CA
Molecular Determinants of Androgen Receptor Pharmacology$346,500
R01 · FY2005 · DK
Development of peptide antagonists of estrogen signaling$400,862
R01 · FY2004 · CA
MECHANISM OF ESTROGENS AND ANTIESTROGENS$358,015
R01 · FY2004 · DK
Molecular Determinants of Androgen Receptor Pharmacology$346,500
R01 · FY2004 · DK
GENETIC DISSECTION OF PROGESTERONE RECEPTOR FUNCTION$283,762
R01 · FY2004 · DK
Conference on Tissue-Selective Nuclear Receptors$10,000
R13 · FY2004 · DK
Nuclear Receptors: Steroid Sisters$6,000
R13 · FY2004 · CA
Development of peptide antagonists of estrogen signaling$389,184
R01 · FY2003 · CA
MECHANISM OF ESTROGENS AND ANTIESTROGENS$347,587
R01 · FY2003 · DK
Molecular Determinants of Androgen Receptor Pharmacology$346,500
R01 · FY2003 · DK
GENETIC DISSECTION OF PROGESTERONE RECEPTOR FUNCTION$283,762
R01 · FY2003 · DK
Development of peptide antagonists of estrogen signaling$377,850
R01 · FY2002 · CA
MECHANISM OF ESTROGENS AND ANTIESTROGENS$337,465
R01 · FY2002 · DK
GENETIC DISSECTION OF PROGESTERONE RECEPTOR FUNCTION$283,762
R01 · FY2002 · DK
PHARMACOLOGY AND EFFICACY OF A NOVEL ANTI-ESTROGEN$179,222
P50 · FY2002 · CA
Development of peptide antagonists of estrogen signaling$350,462
R01 · FY2001 · CA
MECHANISM OF ESTROGENS AND ANTIESTROGENS$324,834
R01 · FY2001 · DK
GENETIC DISSECTION OF PROGESTERONE RECEPTOR FUNCTION$283,762
R01 · FY2001 · DK
MECHANISM OF ESTROGENS AND ANTIESTROGENS$309,991
R01 · FY2000 · DK
GENETIC DISSECTION OF PROGESTERONE RECEPTOR FUNCTION$283,762
R01 · FY2000 · DK
PHARMACOLOGY AND EFFICACY OF A NOVEL ANTI-ESTROGEN$179,222
P50 · FY2000 · CA